Why Puerto Rico Is Having an R&D Moment (And Why Most Companies Are Late to Notice)

Ask a mainland CFO what Puerto Rico is good at and you will usually hear some version of the same answer: pharmaceutical manufacturing, going back to the eighties. That answer is not wrong. It is just about thirty years out of date.

The island that exists today looks different. The plants are still there, and many of them are among the most sophisticated sterile and biologics facilities anywhere under the US regulatory umbrella. But sitting on top of that manufacturing base is something newer and, frankly, more interesting: a real research layer. Process development groups. Analytical method labs. Device engineering teams. Software and data groups supporting regulated operations. Stability and characterization work that used to get shipped back to New Jersey or Indiana and now simply does not.

That shift did not happen because of a press release. It happened the way these things usually happen, which is slowly and then noticeably.

The boring reason this is working

There is a romantic version of this story involving innovation districts and ecosystem maps. Ignore it. The practical reason companies are putting research activity in Puerto Rico is that the island solves a specific and annoying problem.

If you are a US company doing regulated development work, you generally want three things at once. You want to be inside the US legal and regulatory system. You want a cost structure that is not Boston or the Bay Area. And you want engineers and scientists who can pass an audit, read a protocol, and not need six months of onboarding. Those three things almost never show up in the same place.

Puerto Rico is one of the few places where they do. It is a US jurisdiction. FDA oversight is the same FDA oversight. US intellectual property law applies. Your contracts, your courts, your customs posture, your dollar. At the same time the operating cost base is meaningfully below mainland tech and pharma hubs, and the workforce has spent four decades being trained by multinational quality systems.

Add the incentives framework on top of that and the math starts to move.

What the incentives actually do

The current consolidated framework is Act 60-2019, the Puerto Rico Incentives Code. It replaced the patchwork of earlier laws, including Act 73-2008 (Legacy), which was the industrial development statute that a lot of the older decrees on the island were issued under. If you hear someone talk about their "Act 73 decree," they are describing a grandfathered position under a superseded law, not the framework a new project would be built on today.

Under Act 60-2019 §3030.01, research and development activity carries a credit. In the model we work with, the credit is fixed at 50 percent on direct R&D investment deployed in Puerto Rico into experimental activities, and 20 percent on indirect R&D investment deployed outside Puerto Rico or into incidental activities. There is no sliding scale to negotiate and no mystery rate. The entire exercise is figuring out, honestly and defensibly, which dollars belong in which bucket.

That sounds simple. In practice it is where most of the value is won or lost, and it is also where most companies get sloppy.

The part companies underestimate

Here is the uncomfortable truth about R&D credits anywhere, Puerto Rico included. The statute is not usually the hard part. The substantiation is.

A credit claim is only as strong as the record behind it. That means project-level definition of what was actually being developed and what the technical uncertainty was. It means time and cost allocation that ties to real systems and not to a spreadsheet someone built in March for a filing in April. It means being able to explain, to a reviewer who was not in the room, why a particular activity was experimental rather than routine.

Companies that build that record as they go tend to have calm examinations. Companies that reconstruct it afterward tend to have expensive ones.

This is also the reason the direct versus indirect split matters so much. Research carried out on the island, in the lab, against a genuine technical unknown, is the strongest version of the claim. Support work performed elsewhere is a different animal and gets treated accordingly. Pretending otherwise does not make the claim bigger. It makes it fragile.

Who is actually moving

The pattern we see most often is not a company picking up and relocating. It is a company that already has some Puerto Rico footprint, usually manufacturing, deciding to stop treating the island as a pair of hands and start treating it as a brain.

That transition looks like moving process development next to the line instead of five flights away. It looks like standing up an analytical group so that method transfer stops being a quarterly fire drill. It looks like a device company putting verification and validation engineering where the product is actually built.

The second pattern is newer and involves companies with no island history at all. These are usually mid-size firms in technology, medical devices, advanced materials, or specialty manufacturing that have run the numbers on a mainland expansion and did not like what they saw. For them Puerto Rico is not a sentimental choice. It is an arbitrage that happens to be fully inside the US system.

What is on the horizon

Two things make the next few years more interesting than the last few.

The first is reshoring pressure. The supply chain lessons of the last several years did not get unlearned. There is sustained political and commercial appetite for pulling critical production, particularly pharmaceutical and medical, back under domestic control. Puerto Rico is the only place that is simultaneously domestic, already built for that work, and cheaper than the alternatives. That is an unusual position to hold.

The second is that the research layer is starting to compound. When one company stands up an analytical group, it trains people. Some of those people leave and join the next company. The local supplier base thickens. The university pipeline notices and adjusts. None of that happens in a quarter, but it is visibly happening, and it is the difference between a cost center and an ecosystem.

The honest caveats

Nothing here is automatic.

Power reliability remains a real operational planning item and should be budgeted for rather than hoped away. Logistics require more thought than a Midwest site. And the incentives themselves live inside a decree, which means your actual terms, your conditions, and your obligations come from a negotiated document and not from a blog post.

Everything in this article is indicative advisory context. Credit rates, eligibility, phasing, and monetization outcomes depend on your decree, your facts, and current administrative practice, and should be confirmed for your specific situation before you plan around them.

Where to start

If you are evaluating this seriously, the first question is not "how big is the credit." It is "what portion of what we already do would qualify, and can we prove it."

Answer that honestly and the rest of the analysis gets much easier. Answer it optimistically and you will find out the hard way, usually about two years later.

The companies doing well on the island right now are not the ones who found a loophole. They are the ones who did real research in a place that happens to reward it, and kept the paperwork clean while they did it.